Agilent Technologies stock gains on TapeStationDx launch and raised EPS guidance

Agilent Technologies stock (ISIN US00846U1016) traded at USD 156.47 on the NYSE as of September 20, 2026, leaving the shares 1.47 percent below their 52-week high of USD 158.93 and 42.05 percent above the 52-week low of USD 110.24. As ad-hoc-news.de reports, this price level corresponds to a market capitalization of USD 44.11 billion as of September 20, 2026, underlining the group’s substantial weight within the S&P 500 index.

EPS guidance lifted after strong Q3 2026

Agilent Technologies Inc. (NYSE: A) recently delivered a robust third quarter of fiscal year 2026, with earnings per share of USD 1.56 on an ex refund basis, which came in USD 0.06 above the high end of its guidance range of USD 1.48 to USD 1.50 and represented 14 percent year-over-year growth. According to Yahoo Finance on September 21, 2026, total EPS including tariff refunds reached USD 1.62 in Q3 2026, giving management room to raise full-year guidance.

Building on that strong quarter, Agilent increased its full-year fiscal 2026 guidance for EPS to a range of USD 6.18 to USD 6.21, which is USD 0.15 higher at the midpoint than the previous forecast. As highlighted by Yahoo Finance, excluding the net benefit of tariff refunds of approximately USD 0.06 in the third quarter, adjusted full-year EPS is expected in a range of USD 6.12 to USD 6.15, implying growth of around 10 percent at the midpoint compared with the prior year.

Management also stated in the Q3 2026 call that core growth for the full fiscal year is now expected to be between 5.8 percent and 6 percent, reflecting improving conditions in end markets such as clinical and analytical laboratories. According to the same Yahoo Finance transcript, Agilent expects Q4 2026 revenue growth to be flat versus the prior year because it is measured against a very strong quarter that saw about 40 percent year-over-year growth, which sets up a demanding comparison base for investors to watch.

New TapeStationDx systems target regulated clinical labs

Alongside the raised EPS guidance, Agilent has unveiled a new product family that expands its presence in clinical laboratory environments. On September 21, 2026, the company announced the launch of the Agilent 4150 TapeStationDx system, the Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, designed for automated electrophoresis and sample quality control in regulated clinical laboratories working with DNA and RNA. According to Yahoo Finance on September 21, 2026, the TapeStationDx systems are intended for in vitro diagnostic use and extend Agilent’s automated electrophoresis portfolio into regulated clinical laboratory settings.

Coverage of the launch in international media underscores the strategic focus on clinical applications. As Investing.com reported on September 21, 2026, the new TapeStationDx systems and software support quality control of DNA and RNA samples in clinical laboratories, potentially strengthening Agilent’s competitive position in high-growth areas such as clinical genomics and next-generation sequencing workflows.

For investors, the combination of double-digit EPS growth in Q3 2026, raised full-year guidance and the TapeStationDx launch offers a clear narrative of both financial momentum and ongoing product innovation. The company’s previous fiscal year 2025 revenue of USD 6.95 billion, as stated by Yahoo Finance, provides a historical baseline against which the targeted 5.8 to 6 percent core growth in fiscal 2026 can be judged.

Analyst consensus and valuation context

The updated guidance is reflected in analyst expectations. Based on data compiled by MarketBeat on September 21, 2026, analysts currently forecast that Agilent Technologies will post EPS of about USD 6.20 for the current fiscal year 2026, which sits near the upper half of the company’s own guidance range.

In terms of ratings, MarketBeat reports that one covering house maintains a neutral rating on Agilent Technologies stock with a price objective of USD 165.00, while the broader analyst coverage results in an average rating of Moderate Buy and a consensus price target of USD 170.33. Taken together, these views suggest that the market recognizes the company’s growth and profitability improvements but still sees room for upside relative to the September 20, 2026 closing price of USD 156.47.

The price and guidance also need to be interpreted against trading metrics. As noted by ad-hoc-news.de, the stock’s 52-week range of USD 110.24 to USD 158.93 means the September 20, 2026 quote is 14.8 percent above the level at the start of the current 52-week period, illustrating that shareholders have already captured a significant portion of the recent performance while remaining just below the long-term high.

Stock level and what investors are watching

At a closing price of USD 156.47 on the NYSE as of September 20, 2026, Agilent Technologies stock trades close to its 52-week peak and implies a market capitalization of USD 44.11 billion. The shares therefore price in much of the announced EPS growth and guidance improvement, while still standing below the average analyst price target of USD 170.33 cited by MarketBeat.

More news and analyses on Agilent Technologies stock